

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT8387633

|                                                                                                                                                                                                 |                                                                       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|
| SUBMISSION TYPE:                                                                                                                                                                                | NEW ASSIGNMENT                                                        |
| NATURE OF CONVEYANCE:                                                                                                                                                                           | SECURITY INTEREST                                                     |
| CONVEYING PARTY DATA                                                                                                                                                                            |                                                                       |
| Name                                                                                                                                                                                            | Execution Date                                                        |
| VIBLIOME THERAPEUTICS, LLC                                                                                                                                                                      | 12/29/2023                                                            |
| RECEIVING PARTY DATA                                                                                                                                                                            |                                                                       |
| Name:                                                                                                                                                                                           | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS<br>COLLATERAL AGENT |
| Street Address:                                                                                                                                                                                 | 345 PARK AVE SOUT, FLOOR 12                                           |
| City:                                                                                                                                                                                           | NEW YORK                                                              |
| State/Country:                                                                                                                                                                                  | NEW YORK                                                              |
| Postal Code:                                                                                                                                                                                    | 10010                                                                 |
| PROPERTY NUMBERS Total: 7                                                                                                                                                                       |                                                                       |
| Property Type                                                                                                                                                                                   | Number                                                                |
| Patent Number:                                                                                                                                                                                  | 9221805                                                               |
| Patent Number:                                                                                                                                                                                  | 9833455                                                               |
| Application Number:                                                                                                                                                                             | 18196281                                                              |
| Patent Number:                                                                                                                                                                                  | 11629143                                                              |
| Application Number:                                                                                                                                                                             | 17432039                                                              |
| Application Number:                                                                                                                                                                             | 63546320                                                              |
| Application Number:                                                                                                                                                                             | 18577481                                                              |
| CORRESPONDENCE DATA                                                                                                                                                                             |                                                                       |
| Fax Number:                                                                                                                                                                                     | (213)289-7739                                                         |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |                                                                       |
| Phone:                                                                                                                                                                                          | 2134262619                                                            |
| Email:                                                                                                                                                                                          | aarnelle@goodwinlaw.com                                               |
| Correspondent Name:                                                                                                                                                                             | AMY ARNELLE                                                           |
| Address Line 1:                                                                                                                                                                                 | 601 S FIGUEROA STREET SUITE 4100                                      |
| Address Line 4:                                                                                                                                                                                 | LOS ANGELES, CALIFORNIA 90017                                         |
| ATTORNEY DOCKET NUMBER:                                                                                                                                                                         | 151279.359179                                                         |
| NAME OF SUBMITTER:                                                                                                                                                                              | AMY ARNELLE                                                           |
| SIGNATURE:                                                                                                                                                                                      | /Amy Arnelle/                                                         |
| DATE SIGNED:                                                                                                                                                                                    | 01/18/2024                                                            |

**Total Attachments: 8**

source=Vibliome - Patent Security Agreement (12.29.2023) #page1.tif

source=Vibliome - Patent Security Agreement (12.29.2023) #page2.tif

source=Vibliome - Patent Security Agreement (12.29.2023) #page3.tif

source=Vibliome - Patent Security Agreement (12.29.2023) #page4.tif

source=Vibliome - Patent Security Agreement (12.29.2023) #page5.tif

source=Vibliome - Patent Security Agreement (12.29.2023) #page6.tif

source=Vibliome - Patent Security Agreement (12.29.2023) #page7.tif

source=Vibliome - Patent Security Agreement (12.29.2023) #page8.tif

## **PATENT SECURITY AGREEMENT**

This PATENT SECURITY AGREEMENT (this “Agreement”), dated as of December 29, 2023, is made by VIBLIOME THERAPEUTICS, LLC (the “Grantor”), in favor of the Collateral Agent (as such term is defined in the Security Agreement referred to below), for the benefit of itself as collateral agent and for the benefit of the Secured Note Holders (as defined in the Security Agreement referred to below).

WHEREAS, pursuant to the Security Agreement, dated as of December 29, 2023 (as amended, restated, supplemented or otherwise modified from time to time in accordance with the terms thereof, the “Security Agreement”), Grantor has agreed to grant to the Collateral Agent a security interest in all of its Intellectual Property (as defined in the Security Agreement), including the patents and patent applications listed on **Schedule A** hereto;

NOW THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, the Grantor agrees, for the benefit of the Collateral Agent and the Secured Note Holders, as follows:

1. **Definitions.** Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement have the meanings provided or provided by reference in the Security Agreement.

2. **Grant of Security Interest.** The Grantor, as collateral security for the full, prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Obligations, hereby mortgages, pledges and hypothecates to the Collateral Agent, and grants to the Collateral Agent, for the benefit of itself and the Secured Note Holders, a continuing security interest in and Lien upon all of in all of Grantor’s right, title and interest in and to the following, whether now owned or hereafter acquired or arising (collectively, the “Patent Collateral”) (provided, that the Patent Collateral shall exclude the Excluded Collateral (as defined in the Security Agreement)):

- (a) all of its Patents, and all license agreements or other similar agreements providing for the grant by or to the Grantor of any right under any Patent, including, without limitation, those referred to on **Schedule A**;
- (b) all foreign counterparts, reissues, divisionals, continuations in whole or in part, reexaminations, substitutions, and extensions of the foregoing;
- (c) all income, fees, royalties, damages, claims and payments at any time due or payable thereunder and with respect thereto, without limitation, all rights to sue and recover at law or in equity for any past, present or future infringements thereof, and all other rights of any kind accruing thereunder or pertaining thereto throughout the world.

3. **Purpose.** This Agreement has been executed and delivered by the Grantor for the purpose of recording the grant of security interest herein with the United States Patent and Trademark Office. The security interest granted hereby has been granted to the Collateral Agent (for its own benefit and for the benefit of the Secured Note Holders) in connection with the Security Agreement and is expressly subject to the terms and conditions thereof. The provisions of the Security Agreement shall supersede and control over any conflicting or inconsistent provision herein. The Security Agreement (and all rights and remedies of the Collateral Agent and the Secured Note Holders thereunder) shall remain in full force and effect in accordance with its terms.

4. **Acknowledgment.** The Grantor does hereby further acknowledge and affirm that the rights and remedies of the Collateral Agent with respect to the security interest in the Patent Collateral granted

hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the terms of the Security Agreement, the terms of the Security Agreement shall govern.

5. Recordation. Grantor authorizes the Commissioner for Patents in the United States Patent and Trademark Office to record this Agreement upon request by the Collateral Agent.

6. Authorization to Supplement. If the Grantor shall obtain rights to any new patent application or issued patent or become entitled to the benefit of any patent application or patent for any divisional, continuation, continuation-in-part, reissue, or reexamination of any existing patent or patent application contained in the Patent Collateral, the provisions of this Patent Security Agreement shall automatically apply thereto. The Grantor shall give prompt notice in writing to the Collateral Agent with respect to any such new patent rights. Without limiting the Grantor's obligations under this Section, the Grantor hereby authorizes the Collateral Agent unilaterally to modify this Patent Security Agreement by amending Schedule A to include any such new patent rights of the Grantor. Notwithstanding the foregoing, no failure to so modify this Patent Security Agreement or amend Schedule I shall in any way affect, invalidate or detract from the Collateral Agent's continuing security interest in all Patent Collateral, whether or not listed on Schedule A.

7. Grantor Remains Liable. The Grantor hereby agrees that, anything herein to the contrary notwithstanding, it shall assume full and complete responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in connection with the Patent Collateral subject to a security interest hereunder.

8. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together constitute one and the same original.

9. Governing Law. This Agreement and all claims shall be governed by the laws of the State of Delaware, without giving effect to any conflict of law principles except federal laws relating to national banks.

*[Remainder of Page Intentionally Left Blank; Signature Pages Follow.]*

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by their respective officers thereunto duly authorized as of the day and year first above written.

**VIBLIOME THERAPEUTICS, LLC**, as Grantor

DocuSigned by:

*Robert Goodwin*

By: \_\_\_\_\_

E28B5EA9E1B34E7

Name: Robert Goodwin

Title: Director

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by their respective officers thereunto duly authorized as of the day and year first above written.

**DEERFIELD MANAGEMENT COMPANY,  
L.P. (Series C), as Collateral Agent**

By: Flynn Management LLC,  
General Partner

By: \_\_\_\_\_  
Name: David J. Clark  
Title: Authorized Signatory

**SCHEDULE A**

**PATENTS**

**PATENT**

**REEL: 066164 FRAME: 0275**

Vibione Therapeutics LLC  
Active Patent Cases  
CONFIDENTIAL

Version: 10/31/23

| PTO Number         | App No.                           | Att Docket Number | Status | Vib Name                        | Title                                                                                                                       | Inventors                                                          | Assignee                  | Filing Date | Issue Date | Priority Date | Type                                                                                | Jurisdiction |
|--------------------|-----------------------------------|-------------------|--------|---------------------------------|-----------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|---------------------------|-------------|------------|---------------|-------------------------------------------------------------------------------------|--------------|
| US 9,221,805       | 14/173,125                        | 122097-00101      | Issued | Background IP, compositions     | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL,5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | Gary Flynn                                                         | Vibione Therapeutics, LLC | 2/5/14      | 12/29/2015 | 8/3/2012      | Issued, CIP of PCT US2012/049559                                                    | US           |
| US 9,893,455       | 14/939,866                        | 122097-00102      | Issued | Background IP, methods          | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL,5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | Gary Flynn                                                         | Vibione Therapeutics, LLC | 11/12/15    | 12/5/2017  | 8/3/2012      | Issued, Continuation of 9,221,805                                                   | US           |
| EP 2,739,143       | PCT/US2012/049559 EP 12-822,808.7 | 122097-00135      | Issued | Background IP, EU, compositions | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL,5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | Gary Flynn                                                         | Vibione Therapeutics, LLC | 8/9/2012    | 7/11/2018  | 8/3/2012      | Issued EP in UK, Ireland, and France (as 2,739,143) and Germany (as 602012048450.0) | EP           |
| FR of EP 2,739,143 | PCT/US2012/049559 EP 12-822,808.7 | 122097-00185      | Issued | FR Core patent                  | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL,5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | Gary Flynn                                                         | Vibione Therapeutics, LLC | 3/5/2014    | 7/11/2018  | 8/3/2012      | EP Validation Country                                                               | FR           |
| UK of EP 2,739,143 | PCT/US2012/049559 EP 12-822,808.7 | 122097-00186      | Issued | UK Core Patent                  | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL,5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | Gary Flynn                                                         | Vibione Therapeutics, LLC | 3/5/2014    | 7/11/2018  | 8/3/2012      | EP Validation Country                                                               | GB           |
| IE of EP 2,739,143 | PCT/US2012/049559 EP 12-822,808.7 | 122097-00189      | Issued | Ireland Core Patent             | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL,5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | Gary Flynn                                                         | Vibione Therapeutics, LLC | 3/5/2014    | 7/11/2018  | 8/3/2012      | EP Validation Country                                                               | IE           |
| DE 602012048450.0  | PCT/US2012/049559 EP 12-822,808.7 | 122097-00195      | Issued | Germany Core Patent             | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL,5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | Gary Flynn                                                         | Vibione Therapeutics, LLC | 3/5/2014    | 7/11/2018  | 8/3/2012      | EP Validation Country                                                               | DE           |
|                    | 18/196,281                        | 122097-00111      | Active | Background IP, continuation     | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL,5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | Gary A. Flynn                                                      | Vibione Therapeutics, LLC | 5/11/2023   |            | 8/3/2012      | Continuation of Core IP                                                             | US           |
|                    | PCT/US2023/015993                 | 136712-00120      | Active | BRAF Program                    | MODULATORS OF PROTEIN KINASES                                                                                               | Paul Gatats, Doug Werner, Andrew Hurtsman, Kiroi Huynh             | Vibione Therapeutics LLC  | 3/23/2023   |            | 3/24/2022     | PCT application                                                                     | WO           |
|                    | PCT/US2023/016049                 | 136712-00220      | Active | BRAF Program                    | MODULATORS OF PROTEIN KINASES                                                                                               | Paul Gatats, Doug Werner, Andrew Hurtsman, Kiroi Huynh             | Vibione Therapeutics LLC  | 3/23/2023   |            | 3/24/2022     | PCT application                                                                     | WO           |
|                    | 18/577,481                        | 122097-00602      | Active | Pyrazole                        | MODULATORS OF PROTEIN KINASES                                                                                               | Gary Flynn, Paul Gatats, Kiroi Huynh, Andrew Hurtsman, Doug Werner | Vibione Therapeutics LLC  | 1/8/2024    |            |               | US application                                                                      | US           |



|               |            |              |                                                   |                                              |                                            |                                            |                                                                               |            |           |            |                         |    |
|---------------|------------|--------------|---------------------------------------------------|----------------------------------------------|--------------------------------------------|--------------------------------------------|-------------------------------------------------------------------------------|------------|-----------|------------|-------------------------|----|
| US 11,609,143 | 17/490,654 | 122097-00502 | Active (US-only)                                  | HPK4 2020                                    | HPK4 INHIBITORS AND USE THEREOF            | Gary Flynn, Arthur Bull, Knoi Huynh        | Vibione Therapeutics LLC                                                      | 9/30/2021  | 4/18/2023 | 10/1/2020  | Issued                  | US |
|               | 17/432,039 | UTFC-P1381US | Active, US National Phase under PCT/US2020/018850 | HPK4 Inhibitor Co-invention with MD Anderson | HPK4 INHIBITORS AND METHODS OF USE THEREOF | Gary Flynn, Quang Shen                     | Vibione Therapeutics LLC and Board of Regents, The University of Texas System | 8/18/2021  |           | 2/19/2019  | PCT application         | US |
|               | 63/546,320 | 136712-00601 | Active                                            | PLK4                                         | PLK4 Modulators                            | Doug Werner, Kirk Stevens, Frank Hollinger | Vibione Therapeutics LLC                                                      | 10/30/2023 |           | 10/30/2023 | Provisional Application | US |

**Non-Active Cases:**

|               |                    |              |                                   |                                              |                                                                                                                          |                                                                  |                                                                               |            |  |           |                            |    |
|---------------|--------------------|--------------|-----------------------------------|----------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|-------------------------------------------------------------------------------|------------|--|-----------|----------------------------|----|
|               | PCT/US2022/036403  | 122097-00620 | Active                            | Pyrazole                                     | MODULATORS OF PROTEIN KINASES                                                                                            | Gary Flynn, Paul Gates, Knoi Huynh, Andrew Hurstman, Doug Werner | Vibione Therapeutics LLC                                                      | 7/7/2022   |  | 7/8/2021  | PCT application            | WO |
|               | WO 2020/722,296 A1 | UTFC-P1381WO | Filed only, US for National Phase | HPK4 Inhibitor Co-invention with MD Anderson | HPK4 INHIBITORS AND METHODS OF USE THEREOF                                                                               | Gary Flynn, Quang Shen                                           | Vibione Therapeutics LLC and Board of Regents, The University of Texas System | 2/19/2020  |  | 2/19/2019 | PCT application            | WO |
| WO2013/027766 | PCT/US2012/049559  | 122097-00120 | Published/Continued               |                                              | PREPARATION AND METHODS OF USE FOR ORTHOGANARY-SPECIFIC HETEROARYLCARBONAMIDE CONTAINING MULTITARGETED KINASE INHIBITORS | Gary Flynn                                                       |                                                                               | 8/12/2012  |  | 8/5/2011  | PCT application            | WO |
|               | 17/676,319         | 122097-00109 | Abandoned                         | Background IP, continuation                  | PREPARATION AND METHODS OF USE FOR ORTHOGANARY-SPECIFIC HETEROARYLCARBONAMIDE CONTAINING MULTITARGETED KINASE INHIBITORS | Gary A. Flynn                                                    | Vibione Therapeutics, LLC                                                     | 2/7/1/2022 |  | 8/9/2012  | Continuation of 17-386,733 | US |
|               | 17-366,733         | 122097-00108 | Abandoned                         | Background IP, continuation                  | PREPARATION AND METHODS OF USE FOR ORTHOGANARY-SPECIFIC HETEROARYLCARBONAMIDE CONTAINING MULTITARGETED KINASE INHIBITORS | Gary A. Flynn                                                    | Vibione Therapeutics, LLC                                                     | 7/9/2021   |  | 8/9/2012  | Continuation of 17-100,436 | US |
|               | 17-100,436         | 122097-00107 | Abandoned                         | Background IP, continuation                  | PREPARATION AND METHODS OF USE FOR ORTHOGANARY-SPECIFIC HETEROARYLCARBONAMIDE CONTAINING MULTITARGETED KINASE INHIBITORS | Gary Flynn                                                       | Vibione Therapeutics, LLC                                                     | 11/20/2020 |  | 8/9/2012  | Continuation of 16-845,319 | US |
|               | 16-845,319         | 122097-00106 | Abandoned                         | Background IP, continuation                  | PREPARATION AND METHODS OF USE FOR ORTHOGANARY-SPECIFIC HETEROARYLCARBONAMIDE CONTAINING MULTITARGETED KINASE INHIBITORS | Gary Flynn                                                       | Vibione Therapeutics, LLC                                                     | 4/70/2020  |  | 8/9/2012  | Continuation of 16-554,676 | US |
|               | 16-554,676         | 122097-00105 | Abandoned                         | Background IP, continuation                  | PREPARATION AND METHODS OF USE FOR ORTHOGANARY-SPECIFIC HETEROARYLCARBONAMIDE CONTAINING MULTITARGETED KINASE INHIBITORS | Gary Flynn                                                       | Vibione Therapeutics, LLC                                                     | 8/79/2019  |  | 8/9/2012  | Continuation of 16-240,319 | US |
|               | 16-240,319         | 122097-00104 | Abandoned, refiled as 16-554,676  | Background IP, continuation                  | PREPARATION AND METHODS OF USE FOR ORTHOGANARY-SPECIFIC HETEROARYLCARBONAMIDE CONTAINING MULTITARGETED KINASE INHIBITORS | Gary Flynn                                                       | Vibione Therapeutics, LLC                                                     | 1/4/19     |  | 8/9/2012  | Continuation of 15-801,466 | US |

|            |                  |                                    |                                              |                                                                                                                           |                                                                 |                                                                              |            |            |                            |    |
|------------|------------------|------------------------------------|----------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|------------------------------------------------------------------------------|------------|------------|----------------------------|----|
| 15-801,468 | 12/097-00103     | Abandoned, referred as 15-240,279  |                                              | PREPARATION AND METHODS OF USE FOR ORTHOGANIC 5-MEMBERED HETEROCYCLOCARBAMIDES CONTAINING MULTITARGETED KINASE INHIBITORS | Gary Flynn                                                      | Shirell Enterprises LLC                                                      | 11/27/2017 | 8/3/2012   | Continuation of 14-950,846 | US |
| 62-566,661 | 12/097-00101     | Terminated, referred as 62-003,159 |                                              | DESIGN, PREPARATION AND THERAPEUTIC UTILITY OF A NEW CLASS OF TIGHT-BINDING REVERSIBLE PROTEIN INHIBITORS                 | Gary Flynn                                                      |                                                                              | 10/27/2017 | 10/27/2017 | Provisional                | US |
| 62-712,876 | 12/097-00102     | Terminated, referred as 62-003,159 | Irreversible inhibitors                      | METHODS FOR TREATING RESISTANT CANCERS AND OTHER DISEASES                                                                 | Gary Flynn                                                      | Shirell Enterprises LLC                                                      | 10/8/18    | 10/8/18    | Provisional                | US |
| 62-745,595 | 12/097-00103     | Terminated, referred as 62-003,159 | Irreversible inhibitors                      | METHODS OF TREATING RESISTANT CANCERS AND RELATED CONDITIONS                                                              | Gary Flynn                                                      | Visione Therapeutics, LLC                                                    | 10/15/18   | 10/15/18   | Provisional                | US |
| 62-415,295 | 12/097-00104     | Terminated, referred as 62-003,159 |                                              | METHODS OF TREATING RESISTANT CANCERS AND RELATED CONDITIONS                                                              | Gary Flynn                                                      | Visione Therapeutics, LLC (Flynn)                                            | 10/16/2019 | 10/16/2019 | Provisional                | US |
| 62-807,594 | USPC 213811US P1 | Converted to MCO 2020/117,256 A1   | ATK4 Inhibitor Co-invention with MD Anderson | ATK4 INHIBITORS AND METHODS OF USE THEREOF                                                                                | Gary Flynn, Dang Shen                                           | Visione Therapeutics, LLC (Flynn) and University of Texas MD Anderson (Shen) | 2/19/2019  | 2/19/2019  | Provisional                | US |
| 61-760,401 | 12/097-00201     | Terminated                         |                                              | HIGHLY SELECTIVE COVALENT BIACTIVABLE INHIBITORS FOR THE TREATMENT OF CANCERS DEPENDENT ON THIS MUTATION                  | Gary Flynn                                                      |                                                                              | 2/4/2013   | 2/4/2013   | Provisional                | US |
| 61-913,556 | 12/097-00301     | Terminated, referred as 62-637,031 |                                              | UTILITY OF SELECTIVE SMALL MOLECULE ATP4 INHIBITORS                                                                       | Gary Flynn                                                      |                                                                              | 2/24/2014  | 2/24/2014  | Provisional                | US |
| 62-120,450 | 12/097-00302     | Terminated, referred as 62-637,031 |                                              | PREPARATION AND UTILITIES OF SELECTIVE SMALL MOLECULE KINASE INHIBITORS                                                   | Gary Flynn                                                      |                                                                              | 2/25/2015  | 2/25/2015  | Provisional                | US |
| 62-300,167 | 12/097-00303     | Terminated, referred as 62-637,031 |                                              | PREPARATION AND UTILITIES OF SELECTIVE SMALL MOLECULE KINASE INHIBITORS                                                   | Gary Flynn                                                      | Shirell Enterprises LLC                                                      | 2/26/2016  | 2/26/2016  | Provisional                | US |
| 62-464,533 | 12/097-00304     | Terminated, referred as 62-637,031 |                                              | PREPARATION AND UTILITIES OF SELECTIVE SMALL MOLECULE KINASE INHIBITORS                                                   | Gary Flynn                                                      | Shirell Enterprises LLC                                                      | 2/28/2017  | 2/28/2017  | Provisional                | US |
| 62-637,031 | 12/097-00305     | Terminated                         | ATK4 Inhibitors                              | PREPARATION AND UTILITIES OF SELECTIVE SMALL MOLECULE KINASE INHIBITORS                                                   | Gary Flynn                                                      | Visione Therapeutics, LLC                                                    | 3/1/18     | 3/1/18     | Provisional                | US |
| 63-083,359 | 12/097-00405     | Terminated, referred as 63-237,860 | Pleiotropic Provisional                      | METHODS OF TREATING RESISTANT CANCERS AND RELATED CONDITIONS                                                              | Gary Flynn                                                      | Visione Therapeutics LLC                                                     | 10/19/2020 | 10/19/2020 | Provisional                | US |
| 63-257,860 | 12/097-00406     | Terminated                         | Pleiotropic Provisional                      | METHODS OF TREATING RESISTANT CANCERS AND RELATED CONDITIONS                                                              | Gary Flynn                                                      | Visione Therapeutics LLC                                                     | 10/20/2021 | 10/20/2021 | Provisional                | US |
| 63-086,250 | 12/097-00501     | Referred to US-only 17-190         | ATK4 2020 Provisional                        | ATK4 INHIBITORS AND USE THEREOF                                                                                           | Gary Flynn, Anna Ball, Kim Hyatt                                | Visione Therapeutics LLC                                                     | 10/1/2020  | 10/1/2020  | Provisional                | US |
| 63-219,458 | 12/097-00601     | Converted to MCT US2022/036402     | Pyrazole Provisional                         | MODULATORS OF PROTEIN KINASES                                                                                             | Gary Flynn, Paul Galatis, Kim Hyatt, Andrew Hunter, Doug Werner | Visione Therapeutics, LLC                                                    | 7/8/2021   | 7/8/2021   | Provisional                | US |
| 63-323,094 | 136-712-00101    | Converted to MCT US2023/015903     | ATK4 Program                                 | MODULATORS OF PROTEIN KINASES                                                                                             | Paul Galatis, Doug Werner, Kim Hyatt                            | Visione Therapeutics LLC                                                     | 3/23/2023  | 3/24/2022  | Provisional, filed as PCT  | US |
| 63-323,095 | 136-712-00201    | Converted to MCT US2023/016016     | ATK4 Program                                 | MODULATORS OF PROTEIN KINASES                                                                                             | Paul Galatis, Doug Werner, Andrew Hunter, Kim Hyatt             | Visione Therapeutics LLC                                                     | 3/23/2023  | 3/24/2022  | Provisional, filed as PCT  | US |
| 17/553489  | 12/097-00110     | Abandoned                          | Background IP, continuation                  | PREPARATION AND METHODS OF USE FOR ORTHOGANIC 5-MEMBERED HETEROCYCLOCARBAMIDES CONTAINING MULTITARGETED KINASE INHIBITORS | Gary A. Flynn                                                   | Visione Therapeutics, LLC                                                    | 9/27/2022  | 8/3/2012   | Continuation of 17/576,353 | US |